0 Items
Select Page

Rubella Virus Lysate

$426.25 excl. VAT

Purified heat inactivated lysate of native Rubella Virus infected Vero cells.

RUBELLA VIRUS LYSATE

Rubella Virus lysate has been manufactured to provide a consistent source of native Rubella Virus antigen. This material has been produced by culturing Rubella virus in the Vero cell line. This product is suitable for use in a broad range of applications including immunoassay research and development.

 

PRODUCT DETAILS

  • Purified Rubella virus lysate.
  • Propagated in the Vero cell line.
  • Purified by sucrose density gradient ultracentrifugation.
  • Heat inactivated.

 

BACKGROUND

Rubella virus is a single-stranded positive-sense RNA virus. It is the sole member of the Rubivirus genus which belongs to the Togaviridae family of viruses. Humans are the only known host of Rubella virus and infection is spread from person-to-person via respiratory aerosol droplets.

First isolated in 1962, Rubella virus is the causative agent of a highly contagious disease known as Rubella or German Measles. Rubella is an acute self-limiting and generally mild disease predominantly affecting children and young adults. The infection can be asymptomatic in some cases or may cause a mild fever with symptoms of malaise, conjunctivitis and a maculopapular rash (Lambert, N).

However, Rubella virus contracted during the first trimester of pregnancy is of significant health concern, as it  can be passed to the foetus in approximately 90% of cases (WHO). Rubella infection in the foetus can result in miscarriage, foetal death or multiple congenital defects referred to as congenital rubella syndrome (CRS). Congenital defects associated with CRS commonly affect hearing, sight, heart and brain. Other life-long conditions associated with CRS include autism, thyroid dysfunction and diabetes mellitus (CDC).

Rubella infection and vaccination provide >95% chance of developing lifetime immunity. Vaccination, using a live attenuated strain of the virus, has significantly reduced the risk of developing Rubella, and CRS, in countries where a well-established vaccination program is in place. However, many countries still do not include Rubella vaccination in their National immunization programme and women of childbearing age are at high risk of developing Rubella in these areas.

 

REFERENCES

Certificate of Analysis
Safety datasheet

You may also like…

Join our mailing list

* indicates required